Serving 500+ biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving 500+ biopharmaceutical companies globally:
Generated: September 23, 2017
What is the patent landscape for Anoro Ellipta, and when can generic versions of Anoro Ellipta launch?
Anoro Ellipta is a drug marketed by Glaxosmithkline and is included in one NDA. There are thirteen patents protecting this drug.| Patents: | 13 |
| Applicants: | 1 |
| NDAs: | 1 |
| Suppliers / Packagers: see list | 1 |
| Clinical Trials: see list | 25 |
| Drug Prices: | see details |
| DailyMed Link: | ANORO ELLIPTA at DailyMed |
| Drug Class | Anticholinergic beta2-Adrenergic Agonist |
| Mechanism of Action | Cholinergic Antagonists Adrenergic beta2-Agonists |
Export unavailable in trial.
Subscribe for complete access.
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Glaxosmithkline | ANORO ELLIPTA | umeclidinium bromide; vilanterol trifenatate | POWDER;INHALATION | 203975-001 | Dec 18, 2013 | ► Subscribe | ► Subscribe | ||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,361,787 | Phenethanolamine derivatives for treatment of respiratory diseases | ► Subscribe | |||||||||||||
| 8,853,404 | Muscarinic acetylcholine receptor antagonists | ► Subscribe | |||||||||||||
| 9,636,471 | Medicament dispenser | ► Subscribe | |||||||||||||
| 8,575,347 | Muscarinic acetylcholine receptor antagonists | ► Subscribe | |||||||||||||
| 8,198,483 | Phenethanolamine derivatives for treatment of respiratory diseases | ► Subscribe | |||||||||||||
| 7,982,067 | Phenethanolamine derivatives for treatment of respiratory diseases | ► Subscribe | |||||||||||||
| 8,201,556 | Medicament dispenser | ► Subscribe | |||||||||||||
| 9,144,571 | Muscarinic acetylcholine receptor antagonists | ► Subscribe | |||||||||||||
| 9,045,469 | Muscarinic acetylcholine receptor antagonists | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| China | 101272818 | ► Subscribe | |||||||||||||
| Hong Kong | 1089978 | ► Subscribe | |||||||||||||
| European Patent Office | 1425001 | ► Subscribe | |||||||||||||
| European Patent Office | 1534368 | ► Subscribe | |||||||||||||
| Portugal | 1730676 | ► Subscribe | |||||||||||||
| Slovenia | 2042168 | ► Subscribe | |||||||||||||
| European Patent Office | 1534367 | ► Subscribe | |||||||||||||
| European Patent Office | 2570128 | ► Subscribe | |||||||||||||
| China | 101336118 | ► Subscribe | |||||||||||||
| Norway | 20043521 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1740177/02 | Switzerland | ► Subscribe | PRODUCT NAME: UMECLIDINIUM BROMID + VILANTEROL; REGISTRATION NO/DATE: SWISSMEDIC 63152 14.07.2014 | ||||||||||||
| 8 50012-2014 | Slovakia | ► Subscribe | PRODUCT NAME: UMEKLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922/001 - EU/1/14/922/003 20140430 | ||||||||||||
| 1425001/02 | Switzerland | ► Subscribe | PRODUCT NAME: VILANTEROL UND FLUTICASON FUROAT; REGISTRATION NO/DATE: SWISSMEDIC 62969 09.01.2014 | ||||||||||||
| 0694 | Netherlands | ► Subscribe | PRODUCT NAME: UMECLIDINIUMBROMIDE; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140430 | ||||||||||||
| 4 50004-2014 | Slovakia | ► Subscribe | PRODUCT NAME: VILANTEROLTRIFENATAT; REGISTRATION NO/DATE: EU/1/13/886/001 - EU/1/13/886/006 20131113 | ||||||||||||
| 2014038 | Lithuania | ► Subscribe | PRODUCT NAME: UMECLIDINIUM BROMIDIUM; REGISTRATION NO/DATE: EU/1/14/922 20140428 | ||||||||||||
| 565 | Luxembourg | ► Subscribe | PRODUCT NAME: BROMURE D'UMECLIDINUM; FIRST REGISTRATION DATE: 20140428 | ||||||||||||
| 0140013 00103 | Estonia | ► Subscribe | PRODUCT NAME: VILANTEROOLTRIFENATAAT;REG NO/DATE: K(2013)8089 (LOPLIK) 13.11.2013 | ||||||||||||
| C0075 | France | ► Subscribe | PRODUCT NAME: BROMURE D'UMECLIDINIUM; REGISTRATION NO/DATE: EU/1/14/922 001-003 20140428 | ||||||||||||
| 2014000096 | Germany | ► Subscribe | PRODUCT NAME: UMECLIDINIUMBROMID; REGISTRATION NO/DATE: EU/1/14/922/001-003 20140428 | ||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
Serving 500+ biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 22,750 others who get our Drug Patent Expiration Alerts:
